IBD matters How do you treat patients with IBD who are at risk? Education Gastroenterology and Hepatology Partner Content RX View Post
View Post This content is machine translated IBD matters: Module four Molecular mechanisms in pathogenesis and treatment. Studies have shown that altered immune cell transport and pathogenic immune cells are critical factors responsible for mucosal inflammation and tissue destruction in IBD. A defective intestinal barrier and microbial dysbiosis lead to such accumulation and local activation of immune cells, resulting in a pro-inflammatory cytokine loop that overrides anti-inflammatory signals and causes chronic intestinal inflammation. CME-Test
View Post This content is machine translated Chronic inflammatory bowel disease Treatment options for vulnerable patient populations Vulnerable patient populations with inflammatory bowel disease (IBD) require individualized and advanced treatment options. For example, the proportion of childless individuals with IBD is increased, often due to inadequate information about pregnancy in IBD. And treatment in older patients also presents special challenges. Diagnosis takes longer and misdiagnosis is also more common. CME-Test
View Post This content is machine translated Podcast Extraintestinal manifestations and comorbidities Manifestations outside the gatrointestinal tract can additionally have a massive impact on the quality of life of IBD patients. Multidisciplinary collaboration is essential for effective treatment. The treatment spectrum available today ranges from conventional drugs to state-of-the-art biologics and JAK inhibitors. Listen to the second article in the “IBD matters” series for a comprehensive overview of the extraintestinal manifestations of inflammatory bowel disease (IBD).
View Post This content is machine translated Data put in perspective Five years of ustekinumab in Crohn’s disease Long-term data confirm safety and efficacy of ustekinumab: The UNITI study evaluated the efficacy and safety of intravenous induction therapy with ustekinumab followed by subcutaneous maintenance therapy and an extension phase in patients with moderately to severely active Crohn’s disease.
View Post This content is machine translated IBD matters Extraintestinal manifestations and comorbidities Many patients with inflammatory bowel disease (IBD) suffer from disease-associated symptoms outside the gastrointestinal tract. Classic extraintestinal manifestations (EIM) that may occur in association with IBD include rheumatologic, ocular, cutaneous, and hepatobiliary symptoms. The most common EIM are rheumatologic conditions (peripheral arthritis, spondyloarthritis). Anemia is one of the most common comorbidities in patients with IBD. Therefore, this should also be clarified during follow-up and, if necessary, treated by means of iron substitution therapy.
View Post This content is machine translated "IBD matters" Extraintestinal manifestations of inflammatory bowel diseases (IBD) The leading symptoms of inflammatory bowel disease (IBD) are chronic diarrhea (>4 weeks), abdominal pain, bloody stools, and rapid weight loss. IBD is often relapsing, with active phases alternating with inactive phases, and in other cases there is a chronic-active course. Crohn’s disease (MC) and ulcerative colitis (CU) are the main subtypes of IBD – they are systemic diseases associated with extraintestinal manifestations and comorbidities in addition to intestinal complications. CME-Test
View Post This content is machine translated Chronic inflammatory bowel disease (CED) Modern “State-of-the-Art” Pharmacotherapy – an Update Modern approaches to the treatment of inflammatory bowel disease (IBD) are based on the motto “treat-to-target”, whereby in addition to symptom relief and induction of disease remission, the aim nowadays is also to preserve and endoscopically inconspicuous colon mucosa. New agents from the field of biologics and small molecules, which can be used in cases of inadequate response to conventional drugs, are important sources of hope for optimizing therapeutic outcomes. CME-Test
View Post This content is machine translated IBD matters State of the art in IBD treatment The classic symptoms of inflammatory bowel disease (IBD) range from mild abdominal pain to colicky symptoms and persistent diarrhea. Phases of low disease activity may be followed by severe episodes. The etiopathogenesis is thought to be multifactorial, with a combination of endogenous and exogenous factors involved in immune dysregulation, resulting in chronic inflammation in the gut.
